Применение рабепразола в практике гастроэнтеролога
Аннотация
Ингибиторы протонной помпы (ИПП) – класс препаратов с бесспорно высокой эффективностью и хорошим профилем безопасности. С учетом значительного распространения кислотозависимых заболеваний в современном мире ИПП применяются чрезвычайно широко; современная практика без них немыслима. Вместе с тем нельзя не признать, что эти препараты нередко назначаются в отсутствие обоснованных показаний, в неоправданно высоких дозах и в течение чрезмерно длительного времени. В работах последних лет клиницисты и фармацевты призывают ответственно относиться к применению ИПП, в особенности «off label» – вне официальных показаний; в таких случаях необходимо взвешенно обосновывать это в медицинской документации.
Об авторе
Ю. О. Шульпекова
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
к.м.н.
Список литературы
1. Haastrup PF, Paulsen MS, Christensen RD, Søndergaard J, Hansen JM, Jarbøl DE. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther, 2016 Jul, 44(1): 78-87.
2. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol, 2012 May, 5(3): 337-44.
3. Lewis PO, Litchfield JM, Tharp JL, Garcia RM, Pourmorteza M, Reddy CM. Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors, 2016 Jul 25. [Epub ahead of print].
4. Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia: A Systematic Review and Meta-Analysis. PLoS One, 2014, 9(11): e112558.
5. Ro Y, Eun CS, Kim HS, Kim JY, Byun YJ, Yoo KS, Han DS. Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients. Gut Liver, 2016 Jul 15, 10(4): 581-6.
6. Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol, 2013 Jul, 6(4): 443-51.
7. Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Rev Anti Infect Ther, 2005 Dec, 3(6): 863-70.
8. Robert M. Ward, Gregory L. Kearns. Proton Pump Inhibitors in Pediatrics. Paediatr Drugs, 2013 Apr, 15(2): 119-131.
9. Irani S, Krevsky B, Desipio J, Kim-Jaffe J, Maqbool S, Fisher RS. Rapid protection of the gastroduodenal mucosa against aspirininduced damage by rabeprazole. Aliment Pharmacol Ther, 2008 Mar 15, 27(6): 498-503.
10. Wedemeyer R-S, Blume H. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update. Drug Saf, 2014; 37(4): 201-211.
11. Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C, Yin X, Hou Y. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. J Cardiovasc Pharmacol Ther, 2016 Aug 10. pii: 1074248416663647.
12. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL.Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther, 2003 Jun 15, 17(12): 1507-14.
13. Miyashita T, Shah FA, Harmon JW, Marti GP, Matsui D, Okamoto K et al. Do proton pump inhibitors protect against cancer progression in GERD? Surg Today, 2013 Aug, 43(8): 831-7.
14. Miner P et al. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastrooesophageal reflux disease patients with a history of nocturnal heartburn. Aliment Pharmacol Ther, 2010 May, 31(9): 991-1000.
15. Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag, 2007 Jun, 3(3): 363-379.
16. Xia XM, Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterology Research and Practice, 2013: Article ID 327571.
17. Zhao F et al. Helicobacter. 2008 Dec;13(6):532- 41 Yang J-C, Yang Y-F, Uang Y-S, Lin C-J, Wang T-H. Pharmacokinetic-pharmacodynamic analysis of the role of CYP2C19 genotypes in shortterm rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol. 2009 May; 67(5): 503–510.
18. Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab, 2012 Nov, 13(9): 1303-12.
19. McNicholl AG, Linares PM, Nyssen OP et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther, 2012, 36(5): 414-425.
20. Nista EC, Candelli M, Cremonini F, Cazzato IA, Di Caro S, Gabrielli M et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther, 2003, 18: 627-633.
21. Sugimoto M, Sahara S, Ichikawa H, Kagami T, Ban H, Otsuka T, Andoh A, Furuta T. Fourtimes-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. Helicobacter, 2016 May 23. [Epub ahead of print].
22. Tsuchiya M, Imamura L, Park JB, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull, 1995 Aug, 18(8): 1053-6.
23. Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol, 2010 Mar 14, 16(10): 1279-84.
24. Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci, 2003, 48(2): 322-8.
25. Jaworski T, Sarosiek I, Sostarich S, Roeser K, Connor M, Brotze S, Wallner G, Sarosiek J. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci, 2005 Feb, 50(2): 357-65.
26. Garcia CJ, Castro-Combs J, Dias A, Alfaro R, Vasallo J, Majewski M, Jaworski T, Wallner G, Sarosiek J. Impairment of salivary mucin production resulting in declined salivary viscosity during naproxen administration as a potential link to upper alimentary tract mucosal injury. Clin Transl Gastroenterol, 2013 Jul 25, 4: e40.
27. Washio E, Esaki M, Maehata Y, Miyazaki M, Kobayashi H, Ishikawa H, Kitazono T, Matsumoto T. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflam matory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol, 2016 Jun, 14(6): 809-815.
28. Yamasaki Y, Fujimura T, Oyama K, Higashi Y, Hirose A, Tsukada T et al. Effects of rabeprazole on bone metabolic disorders in a gastrectomized rat model. Biomed Rep, 2016 Jul, 5(1): 118–-124.
29. De Milito A, Fais S. Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother, 2005 Jun, 6(7): 1049-54.
30. Pace F, Pallotta S, Casalini Stefano, Porro GB. A review of rabeprazole in the treatment of acidrelated diseases. Ther Clin Risk Manag, 2007 Jun, 3(3): 363-379.
Рецензия
Для цитирования:
Шульпекова Ю.О. Применение рабепразола в практике гастроэнтеролога. Медицинский Совет. 2016;(14):26-31. https://doi.org/10.21518/2079-701X-2016-14-26-31
For citation:
Shulpekova Y.O. Use of Rabeprazol in practice of gastroenterologist. Meditsinskiy sovet = Medical Council. 2016;(14):26-31. (In Russ.) https://doi.org/10.21518/2079-701X-2016-14-26-31
Просмотров: 402
Послать статью по эл. почте 